Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer

NCT ID: NCT02291913

Last Updated: 2020-02-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 48 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-12-18
• Study Completion Date: 2019-01-31

Brief Summary

Many patients with ER-positive or PR-positive breast cancer are treated with endocrine therapy. Although most ER/PR-positive tumors initially respond to hormonal therapy, patients often experience disease progression. Everolimus, in combination with exemestane, has shown activity in endocrine-resistant disease. This study will evaluate the efficacy of Everolimus+ anti-estrogen therapy in patients with ER-positive metastatic breast cancer who have progressed after receiving anti-estrogen therapy.

Detailed Description

This is a multi-centered, open-labeled, Phase II study on metastastic breast cancer (MBC). The patient population includes locally recurrent or MBC patients with cytologically or histologically confirmed hormone receptor-positive breast cancer who have demonstrated disease progression on prior anti-estrogen therapy or therapies. Investigators propose to evaluate the efficacy of Everolimus in patients with ER-positive (estrogen receptor-positive) metastatic breast cancer who have progressed on anti-estrogen therapy. Forty-six (46) patients are planned for enrollment in the trial.

Conditions

Breast Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

everolimus

Everolimus will be administered at a dose of 10 mg PO daily combined with any one of the following anti-estrogen therapies on which the patient most recently progressed (tamoxifen, fulvestrant, anastrozole, letrozole, exemestane, toremifine, or LHRH agonists in conjunction with anti-estrogen therapy). Anti-estrogen therapy will be administered at the US Food and Drug Administration (FDA) prescribed doses.

Group Type: EXPERIMENTAL

Everolimus

Intervention Type: DRUG

Exemestane

Intervention Type: DRUG

Anti-estrogen therapy

Tamoxifen

Intervention Type: DRUG

Anti-estrogen therapy

Fulvestrant

Intervention Type: DRUG

Anti-estrogen therapy

Anastrozole

Intervention Type: DRUG

Anti-estrogen therapy

Letrozole

Intervention Type: DRUG

Anti-estrogen therapy

Toremifine

Intervention Type: DRUG

Anti-estrogen therapy

Interventions

Everolimus

Intervention Type: DRUG

Exemestane

Anti-estrogen therapy

Intervention Type: DRUG

Tamoxifen

Anti-estrogen therapy

Intervention Type: DRUG

Fulvestrant

Anti-estrogen therapy

Intervention Type: DRUG

Anastrozole

Anti-estrogen therapy

Intervention Type: DRUG

Letrozole

Anti-estrogen therapy

Intervention Type: DRUG

Toremifine

Anti-estrogen therapy

Intervention Type: DRUG

Other Intervention Names

Afinitor

Eligibility Criteria

Inclusion Criteria

1. Histologic diagnosis of unresectable, locally recurrent or MBC.

2. ER and/or PR-positive tumors with staining by immunohistochemistry (IHC) based on the most recent biopsy.

3. Only 1 previous chemotherapy regimen for MBC. Patients progressing while receiving adjuvant endocrine therapy or progressing <12 months from completion of adjuvant endocrine therapy are eligible.

4. Progressed on anti-estrogen therapy (tamoxifen, fulvestrant, anastrozole, letrozole, exemestane, toremifine, or LHRH agonists in conjunction with anti-estrogen therapy) defined as:

• Recurrence while on, or within 12 months of end of anti-estrogen therapy for early stage breast cancer, or
• Progression while on, or within one month of anti-estrogen therapy for locally advanced or metastatic breast cancer.

Note: No washout for anti-estrogen therapy required. Anti-estrogen therapy does not have to be the last treatment prior to study entry.

5. Post-menopausal or pre/peri-menopausal women on tamoxifen. LHRH agonists may be used to render ovarian suppression with postmenopausal ranges of estradiol or FSH per institutional guidelines.

6. HER2-negative breast cancer, defined as follows:

• Fluorescent In Situ Hybridization (FISH)-negative (FISH ratio <2.0), or
• IHC 0-1+, or
• IHC 2-3+ AND FISH-negative (FISH ratio <2.0).

7. Measureable disease as measured by Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 or evaluable bone lesions, lytic or mixed, in absence of measureable disease by RECIST criteria.

8. Adequate hematologic, hepatic and renal function.

9. International normalized ratio (INR) ≤1.5 or prothrombin time (PT)/partial thromboplastin time (PTT) within normal limits (WNL) of the institution (if patient is not on anti-coagulation therapy).

10. Age ≥ 18 years.

11. ECOG Performance Status score of 0-2.

12. Life expectancy of ≥ 12 weeks.

Exclusion Criteria

1. Previous therapy or known intolerance/hypersensitivity with any approved or investigational mTOR inhibitor (e.g., temsirolimus, everolimus, sirolimus).

2. Patients who are ≤21 days after their most recent chemotherapy and have not recovered from side effects.

3. Use of an investigational drug ≤21 days or 5 half-lives (whichever is shorter) prior to the first dose of everolimus. For investigational drugs for which 5 half-lives is ≤21 days, a minimum of 10 days between termination of the investigational drug and administration of everolimus is required.

4. Wide field radiotherapy (including therapeutic radioisotopes such as strontium 89) administered ≤28 days or limited field radiation for palliation ≤7 days for metastatic disease prior to first dose of everolimus or has not recovered from side effects of such therapy.

5. Previously untreated brain metastases. Patients who have received radiation or surgery for brain metastases are eligible if there is no evidence of central nervous system (CNS) disease progression, and at least 2 weeks have elapsed since treatment. Patients are not permitted to receive enzyme inducing anti-epileptic drugs (EIAEDs) during the study and should not be receiving chronic corticosteroid therapy for CNS metastases.

6. Patients with known active hepatitis B (HBV) or hepatitis C (HCV) infection. Patients with risk factors for hepatitis must have HBV DNA and HCV RNA testing by PCR, and are ineligible if these tests are positive.

7. Patients receiving immunization with attenuated live vaccines within 1 week of study entry or during study period.

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Novartis

INDUSTRY

Sponsor Role: collaborator

SCRI Development Innovations, LLC

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Denise A. Yardley, MD

Role: STUDY_CHAIR

SCRI Development Innovations, LLC

Locations

Florida Cancer Specialists-South

Fort Myers, Florida, United States

Memorial Cancer Center

Hollywood, Florida, United States

Woodlands Medical Specialists

Pensacola, Florida, United States

Florida Cancer Specialists-East

West Palm Beach, Florida, United States

Hope Cancer Center

Terre Haute, Indiana, United States

Tennessee Oncology

Chattanooga, Tennessee, United States

Tennessee Oncology PLLC

Nashville, Tennessee, United States

Center for Cancer and Blood Disorders

Fort Worth, Texas, United States

Countries

United States

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

SCRI BRE 212

Identifier Type: -

Identifier Source: org_study_id